ArticleFrontiers in immunology2019
Donor Allospecific CD44
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Intrinsic tumor cell line immunogenicity may drive CAR-independent T cell responses and confound CAR T cell preclinical modeling.Journal for immunotherapy of cancer · 2026Article
- Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatment.Journal of experimental & clinical cancer research : CR · 2025Article
- Kinetics of Recovery of Naïve and Memory T Cells in Acute Leukemia Patients after Allogeneic Stem Cell Transplantation Depending on Different GVHD Prophylaxis Regimens.International journal of hematology-oncology and stem cell research · 2024Article
- TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses.Cancer immunology, immunotherapy : CII · 2023Article
- Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.Frontiers in immunology · 2022Review
- Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia: Innocent or Guilty?Frontiers in immunology · 2022Review
- Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells.Clinical and translational medicine · 2021Article
- Article
- Article
- The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.Blood · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Data from both animal models and humans have demonstrated that effector memory T cells (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.